Literature DB >> 16278524

Systemic hypertension among women with uterine leiomyomata: potential final common pathways of target end-organ remodeling.

Marc A Silver1, Rashmi Raghuvir, Bohdan Fedirko, Denise Elser.   

Abstract

The uterus and the heart share a common structure and may remodel in a similar fashion, albeit temporally distinct. The authors investigated the prevalence of systemic hypertension in women with uterine leiomyomata (fibroids) and compared the prevalence in women undergoing hysterectomy for other reasons as well as in age-matched women from the National Health and Nutrition Examination Survey III (NHANES III). A total of 584 women, 205 with leiomyomata in 1999 (group A) and 379 who underwent hysterectomy for a variety of reasons in 2000 (group B) at Advocate Christ Medical Center were included. Presence of leiomyomata was confirmed by pathology. Hypertension was defined as blood pressure > or = 140/90 mm Hg or history of hypertension with or without medication use. The prevalence of hypertension in group A and B patients with leiomyomata compared with NHANES III overall was 48.6% vs. 24% (p<0.001), in African Americans 55.5% vs. 32.4% (p<0.001), and in Caucasians 51.1% vs. 23.3% (p<0.001). Leiomyomata were more frequent among hypertensive than normotensive women (57% vs. 27%). Caucasian and African-American women with leiomyomata were significantly younger and more likely to use hormone replacement therapy than others. Thus there appears to be an association between leiomyomata and hypertension, which needs to be explored in future prospective trials.

Entities:  

Mesh:

Year:  2005        PMID: 16278524      PMCID: PMC8109386          DOI: 10.1111/j.1524-6175.2005.04384.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  15 in total

1.  Fibroids and hypertension. A cross-sectional study of women undergoing hysterectomy.

Authors:  R Luoto; E M Rutanen; A Auvinen
Journal:  J Reprod Med       Date:  2001-04       Impact factor: 0.142

2.  The blood pressure response to infusions of angiotensin II during normal pregnancy: relation to plasma angiotensin II concentration, serum progesterone level, and mean platelet volume.

Authors:  M Ito; T Nakamura; T Yoshimura; H Koyama; H Okamura
Journal:  Am J Obstet Gynecol       Date:  1992-04       Impact factor: 8.661

3.  Regulation of uterine angiotensin II receptors by estrogen and progesterone.

Authors:  A Schirar; A Capponi; K J Catt
Journal:  Endocrinology       Date:  1980-01       Impact factor: 4.736

4.  Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy.

Authors:  Q Dou; Y Zhao; R W Tarnuzzer; H Rong; R S Williams; G S Schultz; N Chegini
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

5.  Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.

Authors:  J E Bishop; L A Kiernan; H E Montgomery; P Gohlke; J R McEwan
Journal:  Cardiovasc Res       Date:  2000-07       Impact factor: 10.787

6.  Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991.

Authors:  V L Burt; P Whelton; E J Roccella; C Brown; J A Cutler; M Higgins; M J Horan; D Labarthe
Journal:  Hypertension       Date:  1995-03       Impact factor: 10.190

7.  The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer.

Authors:  M Nakajima; H G Hutchinson; M Fujinaga; W Hayashida; R Morishita; L Zhang; M Horiuchi; R E Pratt; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

8.  Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II.

Authors:  H Itoh; M Mukoyama; R E Pratt; G H Gibbons; V J Dzau
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

Authors:  Ihab Hajjar; Theodore A Kotchen
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

10.  Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall.

Authors:  M J Daemen; D M Lombardi; F T Bosman; S M Schwartz
Journal:  Circ Res       Date:  1991-02       Impact factor: 17.367

View more
  10 in total

1.  Cardiovascular risk factors and diseases in women undergoing hysterectomy with ovarian conservation.

Authors:  Shannon K Laughlin-Tommaso; Zaraq Khan; Amy L Weaver; Cathy D Schleck; Walter A Rocca; Elizabeth A Stewart
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

2.  Hypertension and risk of uterine leiomyomata in US black women.

Authors:  R G Radin; L Rosenberg; J R Palmer; Y C Cozier; S K Kumanyika; L A Wise
Journal:  Hum Reprod       Date:  2012-02-26       Impact factor: 6.918

3.  Enodthelin 1 is elevated in plasma and explants from patients having uterine leiomyomas.

Authors:  Kedra Wallace; Krystal Chatman; Justin Porter; Jeremy Scott; Venessia Johnson; Janae Moseley; Babbette LaMarca
Journal:  Reprod Sci       Date:  2014-09       Impact factor: 3.060

Review 4.  New directions in the epidemiology of uterine fibroids.

Authors:  Shannon K Laughlin; Jane C Schroeder; Donna Day Baird
Journal:  Semin Reprod Med       Date:  2010-04-22       Impact factor: 1.303

Review 5.  Epidemiology of Uterine Fibroids: From Menarche to Menopause.

Authors:  Lauren A Wise; Shannon K Laughlin-Tommaso
Journal:  Clin Obstet Gynecol       Date:  2016-03       Impact factor: 2.190

6.  Evaluation of cardiovascular risk factors in women with uterine leimyoma: is there a link with atherosclerosis?

Authors:  Nasir Sivri; Tülin Yalta; Cenk Sayın; Kenan Yalta; Fulya Ozpuyan; Ebru Taştekin; Ertan Yetkin
Journal:  Balkan Med J       Date:  2012-09-01       Impact factor: 2.021

7.  Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women.

Authors:  Nicole M Fischer; Tim O Nieuwenhuis; Bhuchitra Singh; Gayane Yenokyan; James H Segars
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

8.  Uterine Fibroids and the Risk of Cardiovascular Disease in the Coronary Artery Risk Development in Young Adult Women's Study.

Authors:  Shannon K Laughlin-Tommaso; Erika L Fuchs; Melissa F Wellons; Cora E Lewis; Ronit Calderon-Margalit; Elizabeth A Stewart; Pamela J Schreiner
Journal:  J Womens Health (Larchmt)       Date:  2018-11-09       Impact factor: 3.017

9.  Evidence of selection as a cause for racial disparities in fibroproliferative disease.

Authors:  Jacklyn N Hellwege; Eric S Torstenson; Shirley B Russell; Todd L Edwards; Digna R Velez Edwards
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

10.  The association between subclinical atherosclerosis and uterine fibroids.

Authors:  Yuan He; Qiang Zeng; Xiaohui Li; Baohua Liu; Peiyu Wang
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.